Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–6 of 6 results
Advanced filters: Author: Thomas Marjot Clear advanced filters

  • This Review provides mechanistic and clinical insights into COVID-19 in the context of liver disease, discussing the potential underlying biology and clinical features of SARS-CoV-2 infection in patients with pre-existing liver conditions. The management of these patients is also discussed, including SARS-CoV-2 vaccination strategies.

    • Thomas Marjot
    • Gwilym J. Webb
    • Eleanor Barnes
    Reviews
    Nature Reviews Gastroenterology & Hepatology
    Volume: 18, P: 348-364

  • Consumption of no and low-alcohol (NoLo) beverages is now commonplace in modern society. However, the debate surrounding the relative risks and benefits of these products is nuanced and evolving, particularly in patients with a history of alcohol use disorder or alcohol-related liver disease. This Comment summarizes the major individual and public health implications of NoLo drinks in order to help inform our interactions with these patient groups.

    • Thomas Marjot
    • Ashwin Dhanda
    Comments & Opinion
    Nature Reviews Gastroenterology & Hepatology
    Volume: 22, P: 3-4

  • Serological analysis and infection outcomes of participants in the multi-center, prospectively enrolled OCTAVE cohort, comprising 2,686 participants with immune-suppressive diseases who recieved two COVID-19 vaccines, reveals specific clinical phenotypes that might benefit from specific COVID-19 therapeutic strategies.

    • Eleanor Barnes
    • Carl S. Goodyear
    • Deborah Richardson
    ResearchOpen Access
    Nature Medicine
    Volume: 29, P: 1760-1774

  • FXR regulates the levels of ACE2 in tissues of the respiratory and gastrointestinal systems that are affected by COVID-19, and inhibiting FXR with ursodeoxycholic acid downregulates ACE2 and reduces susceptibility to SARS-CoV-2 infection.

    • Teresa Brevini
    • Mailis Maes
    • Fotios Sampaziotis
    ResearchOpen Access
    Nature
    Volume: 615, P: 134-142

  • Understanding the effect of vaccination on emerging SARS-CoV-2 variants of concern is of increasing importance. Here, James et al. report that two doses of vaccination with the Pfizer-BioNTech vaccine induce more robust immune responses to the B.1.1.7 and B.1.351 SARS-CoV-2 lineages than does natural infection.

    • Donal T. Skelly
    • Adam C. Harding
    • William S. James
    ResearchOpen Access
    Nature Communications
    Volume: 12, P: 1-12